ClinicalTrials.gg
CompletedNCT04736199ARANOTEUpdated Sep 29, 2026Results posted

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

A Phase 3 interventional study of Darolutamide (Nubeqa, BAY1841788) and Placebo in Prostatic Neoplasms, sponsored by Bayer. Completed at 131 sites in 15 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Updated Sep 29, 2026Study documents postedPosted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
669
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
7th of 59
669 · median 80
Started
2021
with 8 others
Phase 3
12 of 59
5 open now
Registered
22nd of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 7th largest by enrollment, is one of 9 that started in 2021, is one of 12 in phase 3, and was the 22nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Metastatic hormone-sensitive prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of prostate
  • disease
  • Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but not earlier than 12 weeks before randomization
  • (ECOG) Performance Status (PS) of 0, 1 or 2
  • Adequate bone marrow, liver and renal function

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with: LHRH agonist/antagonists except and /or adjuvant therapy; Second-generation androgen receptor (AR) inhibitors such as enzalutamide, darolutamide, apalutamide or other AR inhibitors; Cytochrome P17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as anti-cancer treatment for prostate cancer; Chemotherapy including docetaxel or immunotherapy for prostate cancer; Use of systemic with dose greater than the equivalent 10 mg of prednisone/day within 28 days prior to randomization; Radiopharmaceuticals; Any other anti-cancer treatment for prostate cancer, excluding local therapies and ADT.
  • Treatment with radiotherapy within 2 weeks before randomization
  • to iodinated CT and gadolinium chelate MRI intravenous contrast agent(s)
  • Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure ( Class III or IV)
  • Uncontrolled hypertension as indicated by a resting systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite medical management
  • A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of study drug
  • Any prior (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization
  • Inability to swallow oral medications
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
669 participants (actual)

Study arms

  • Experimental
    Darolutamide+ADT

    Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy

    Drug: Darolutamide (Nubeqa, BAY1841788) · Other: Androgen deprivation therapy (ADT)

  • Placebo comparator
    Placebo+ADT

    Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy

    Drug: Placebo · Other: Androgen deprivation therapy (ADT)

Interventions

  • Coated tablet, oral administration

  • DrugPlacebo

    Coated tablet matching Darolutamide in appearance, oral administration

  • OtherAndrogen deprivation therapy (ADT)

    Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy

06

What researchers measure

Primary outcomes

  1. Radiological Progression-free Survival (rPFS) Assessed by Central Review

    rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria.

    Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months

Secondary outcomes

  1. Overall Survival (OS)

    Time from the date of randomization to the date of death from any cause.

    Time frame: From randomization to the final analysis date, approximately 47 months

  2. Time to Castration-Resistant Prostate Cancer (CRPC)

    Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first).

    Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months

  3. Time to Initiation of Subsequent Anti-cancer Therapy

    Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer.

    Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months

  4. Time to PSA Progression

    Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level \<0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels \<0.50 ng/mL is requested at initial assessment.

    Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months

  5. PSA Undetectable Rates (<0.2 ng/mL)

    Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values \<0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline.

    Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months

  6. Time to Pain Progression

    Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale \[WPS\]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS \>0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization.

    Time frame: From randomization to the date when 222 rPFS events were observed, approximately 36 months

  7. Number of Participants With Adverse Events as a Measure of Safety

    An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug.

    Time frame: From start of study drug administration until 30 days after the last administration

07

Results

Posted Aug 8, 2025

Participant flow

Study was conducted at 133 centers in Europe/Rest of the world (ROW), Asia, and Latin America between 23-Feb-2021 (first participant first visit) and 23-Jan-2026 (last participant last visit).

Double-blind Period
Participant flow — Double-blind Period
MilestoneDarolutamide+ADTPlacebo+ADT
Started446223
Treated443223
Completed23161
Not completed215162
Withdrew: Adverse event3022
Withdrew: Death93
Withdrew: Lost to follow-up41
Withdrew: Physician decision59
Withdrew: Withdrawal by subject229
Withdrew: Progressive disease124102
Withdrew: Subject decision1313
Withdrew: Required study drug interruption longer than allowed per protocol30
Withdrew: Additional primary malignancy10
Withdrew: Non-compliance with study drug02
Withdrew: Other reason11
Withdrew: Study drug never administered30
Open-label Period
Participant flow — Open-label Period
MilestoneDarolutamide+ADTPlacebo+ADT
Started23160
Completed23160
Not completed00

Outcome measures

PrimaryRadiological Progression-free Survival (rPFS) Assessed by Central Review

rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria.

Time frame:
From randomization to the date when 222 rPFS events were observed, approximately 36 months
Reported as:
Median · Months
Radiological Progression-free Survival (rPFS) Assessed by Central Review
MonthsDarolutamide+ADTPlacebo+ADT
Radiological Progression-free Survival (rPFS) Assessed by Central ReviewNA (NA to NA)25.0 (19.0 to NA)
Statistical analysis
  • Darolutamide+ADT vs Placebo+ADT · Log Rank · p = <0.0001 (One-sided) · Hazard ratio (hr): 0.541 · 95% CI 0.413 to 0.707
SecondaryOverall Survival (OS)

Time from the date of randomization to the date of death from any cause.

Time frame:
From randomization to the final analysis date, approximately 47 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsDarolutamide+ADTPlacebo+ADT
At primary completion cut-offNA (NA to NA)NA (33.8 to NA)
At final analysis cut-offNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Darolutamide+ADT vs Placebo+ADT · Log Rank · p = 0.1007 (One-sided) · Hazard ratio (hr): 0.813 · 95% CI 0.591 to 1.118significance level of 0.0185 (one-sided)
  • Darolutamide+ADT vs Placebo+ADT · Log Rank · p = 0.0473 (One-sided) · Hazard ratio (hr): 0.776 · 95% CI 0.577 to 1.045significance level of 0.0202 (one-sided)
SecondaryTime to Castration-Resistant Prostate Cancer (CRPC)

Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first).

Time frame:
From randomization to the date when 222 rPFS events were observed, approximately 36 months
Reported as:
Median · Months
Time to Castration-Resistant Prostate Cancer (CRPC)
MonthsDarolutamide+ADTPlacebo+ADT
Time to Castration-Resistant Prostate Cancer (CRPC)NA (NA to NA)13.8 (12.0 to 16.8)
Statistical analysis
  • Darolutamide+ADT vs Placebo+ADT · Hazard ratio (hr): 0.404 · 95% CI 0.321 to 0.508
SecondaryTime to Initiation of Subsequent Anti-cancer Therapy

Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer.

Time frame:
From randomization to the date when 222 rPFS events were observed, approximately 36 months
Reported as:
Median · Months
Time to Initiation of Subsequent Anti-cancer Therapy
MonthsDarolutamide+ADTPlacebo+ADT
Time to Initiation of Subsequent Anti-cancer TherapyNA (NA to NA)NA (27.7 to NA)
Statistical analysis
  • Darolutamide+ADT vs Placebo+ADT · Hazard ratio (hr): 0.401 · 95% CI 0.288 to 0.558
SecondaryTime to PSA Progression

Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level \<0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels \<0.50 ng/mL is requested at initial assessment.

Time frame:
From randomization to the date when 222 rPFS events were observed, approximately 36 months
Reported as:
Median · Months
Time to PSA Progression
MonthsDarolutamide+ADTPlacebo+ADT
Time to PSA ProgressionNA (NA to NA)16.8 (13.9 to 20.1)
Statistical analysis
  • Darolutamide+ADT vs Placebo+ADT · Hazard ratio (hr): 0.306 · 95% CI 0.231 to 0.405
SecondaryPSA Undetectable Rates (<0.2 ng/mL)

Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values \<0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline.

Time frame:
From randomization to the date when 222 rPFS events were observed, approximately 36 months
Reported as:
Number · Percentage of participants
PSA Undetectable Rates (<0.2 ng/mL)
Percentage of participantsDarolutamide+ADTPlacebo+ADT
PSA Undetectable Rates (<0.2 ng/mL)62.6 (57.8 to 67.2)18.5 (13.5 to 24.4)
Statistical analysis
  • Darolutamide+ADT vs Placebo+ADT · Rate difference: 44.3 · 95% CI 37.4 to 51.2
SecondaryTime to Pain Progression

Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale \[WPS\]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS \>0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization.

Time frame:
From randomization to the date when 222 rPFS events were observed, approximately 36 months
Reported as:
Median · Months
Time to Pain Progression
MonthsDarolutamide+ADTPlacebo+ADT
Time to Pain ProgressionNA (NA to NA)29.9 (29.7 to NA)
Statistical analysis
  • Darolutamide+ADT vs Placebo+ADT · Hazard ratio (hr): 0.721 · 95% CI 0.544 to 0.957
SecondaryNumber of Participants With Adverse Events as a Measure of Safety

An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug.

Time frame:
From start of study drug administration until 30 days after the last administration
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events as a Measure of Safety
ParticipantsDarolutamide (DB)Darolutamide (DB + OL)Placebo (DB)Placebo - Darolutamide (CO)
Any TEAE40740919930
Any TESAE109126528
Any study drug-related TEAE147154648

Adverse events

Collected over From start of study drug administration until 30 days after the last administration. All-cause mortality death events at any time during the study (approximately 59 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Darolutamide (DB)123/446 (27.6%)109/446 (24.4%)329/446 (73.8%)
Darolutamide (DB + OL)126/446 (28.3%)126/446 (28.3%)341/446 (76.5%)
Placebo (DB)76/220 (34.5%)52/220 (23.6%)156/220 (70.9%)
Placebo - Darolutamide (CO)2/59 (3.4%)8/59 (13.6%)14/59 (23.7%)
Most frequent serious events
Showing 10 of 190
Most frequent serious events
EventDarolutamide (DB)Darolutamide (DB + OL)Placebo (DB)Placebo - Darolutamide (CO)
Urinary tract infectionInfections and infestations8/4468/4461/2200/59
Myocardial infarctionCardiac disorders3/4463/4460/2201/59
CellulitisInfections and infestations1/4461/4461/2201/59
InfectionInfections and infestations1/4461/4460/2201/59
Liver abscessInfections and infestations1/4461/4460/2201/59
FallInjury, poisoning and procedural complications0/4460/4461/2201/59
ArthritisMusculoskeletal and connective tissue disorders0/4460/4460/2201/59
Intestinal obstructionGastrointestinal disorders0/4460/4460/2201/59
AppendicitisInfections and infestations0/4460/4460/2201/59
PneumoniaInfections and infestations6/4467/4462/2200/59
Most frequent other events
Showing 10 of 22
Most frequent other events
EventDarolutamide (DB)Darolutamide (DB + OL)Placebo (DB)Placebo - Darolutamide (CO)
AnaemiaBlood and lymphatic system disorders94/446106/44637/2204/59
ArthralgiaMusculoskeletal and connective tissue disorders57/44661/44626/2200/59
Bone painMusculoskeletal and connective tissue disorders31/44631/44627/2200/59
Urinary tract infectionInfections and infestations49/44650/44619/2200/59
ConstipationGastrointestinal disorders48/44649/44616/2200/59
Back painMusculoskeletal and connective tissue disorders46/44648/44622/2200/59
Aspartate aminotransferase increasedInvestigations45/44646/44617/2201/59
HypertensionVascular disorders39/44644/44619/2201/59
Pain in extremityMusculoskeletal and connective tissue disorders41/44643/44619/2201/59
Alanine aminotransferase increasedInvestigations40/44642/44619/2201/59

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Darolutamide+ADTPlacebo+ADTTotal
Mean69.6 ± 8.869.2 ± 8.969.5 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Darolutamide+ADTPlacebo+ADTTotal
Female000
Male446223669
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Darolutamide+ADTPlacebo+ADTTotal
Hispanic or Latino10458162
Not Hispanic or Latino334157491
Unknown or Not Reported8816
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Darolutamide+ADTPlacebo+ADTTotal
White251125376
Black or African American412465
Asian14465209
Other10919
08

Study locations

131 sites
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Northern Cancer Institute
    St Leonards, New South Wales 2065, Australia
  • Macquarie University Hospital - Oncology Department
    Sydney, New South Wales 2109, Australia
  • Cancer Research South Australia
    Adelaide, South Australia 5000, Australia
  • Peninsula Oncology Centre
    Frankston, Victoria 3199, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Assistência Multidisciplinar em Oncologia (AMO)
    Salvador, Estado de Bahia 41950-640, Brazil
  • Hosp. Araujo Jorge da Associação de Combate ao Câncer
    Goiânia, Goiás 74605-070, Brazil
  • Hospital da Universidade Federal de Minas Gerais
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Cetus Oncologia Hospital Dia
    Belo Horizonte, Minas Gerais 30150-270, Brazil
  • Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner
    Curitiba, Paraná 81520-060, Brazil
  • Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica
    Natal, Rio Grande do Norte 59040-000, Brazil
  • Unidade de Pesquisas Clinicas em Oncologia
    Pelotas, Rio Grande do Sul 96020-080, Brazil
  • Santa Casa de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Hospital Mae de Deus
    Porto Alegre, Rio Grande do Sul 90850-170, Brazil
  • FZ Pesquisa e Servicos em Cardiologia | Porto Alegre, Brazil
    Porto Alegre, Rio Grande do Sul 91350-280, Brazil
  • Fundacao Pio XII - Hospital de Cancer de Barretos
    Barretos/SP, São Paulo 14784-400, Brazil
  • Hospital de Base | Funfarme - Centro Integrado de Pesquisa - Cardiologia
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Urobrasil
    São Paulo, São Paulo 01243-020, Brazil
  • IBCC - Instituto Brasileiro de Controle do Cancer
    São Paulo, São Paulo 03102-002, Brazil
  • Inst. de Assistência Médica ao Sérvidor Público Estadual
    São Paulo, São Paulo 04039-004, Brazil
  • Instituto COI de Educação e Pesquisa
    Rio de Janeiro, 22793-080, Brazil
  • G. Kenneth Jansz Medicine Professional Corporation
    Burlington, Ontario L7N 3V2, Canada
  • Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
    Montreal, Quebec H2X 0A9, Canada
  • Centro de Investigación Clínica del Sur
    Temuco, Araucania 4781156, Chile
  • Centro de Estudios Clínicos SAGA SpA
    Providencia, Santiago Metropolitan 7500653, Chile
  • OncoCentro
    Viña del Mar, Valparaiso 2520598, Chile
  • Fundación Arturo López Perez
    Santiago, 7500921, Chile
  • Oncovida
    Santiago, 7510032, Chile
  • Hospital Clínico de la Pontificia Univ. Católica de Chile
    Santiago, TBC, Chile
  • UROMED
    Santiago, Chile
  • Anhui Provincial Hospital
    Hefei City, Anhui Province, Anhui 230031, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510000, China
  • Guangzhou First People Hospital
    Guangzhou, Guangdong 510180, China
  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
    Shenzhen, Guangdong 518172, China
  • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
    Wuhan, Hubei 430030, China
  • Zhongnan hospital ,Wuhan University
    Wuhan, Hubei 430071, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital - Oncology Department
    Changsha, Hunan 410013, China
  • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
    Nanjing, Jiangsu 210008, China
  • Nantong tumor hospital
    Nantong, Jiangsu 226361, China
  • The 2nd Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215004, China
  • 1st Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Liaoning Cancer Hospital and Institute
    Shengyang, Liaoning 110042, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi 710061, China
  • SichuanAcademyofMedicalSciences&SichuanProvincialPeople'sHos
    Chengdu, Sichuan 610072, China
  • Sichuan University West China Hospital
    Chengdu, Sichuan MISSING, China
  • The 1st Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang 310000, China
  • ZheJiang Provincial People's Hospital
    Hangzhou, Zhejiang 310014, China
  • Ningbo First Hospital
    Ningbo, Zhejiang 315010, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, 100000, China
  • Peking University Third Hospital
    Beijing, 100083, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Mahatma Gandhi Cancer Hospital & Research Institute
    Visakhapatnam, Andhra Pradesh 530017, India
  • The Gujarat Cancer & Research Institute
    Ahmedabad, Gujarat 380016, India
  • HCG Cancer Centre - Ahmedabad
    Ahmedabad, Gujarat 380060, India
  • Cancer Care Clinic - Vadodara
    Vadodara, Gujarat 390007, India
  • K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
    Belagavi, Karnataka 590010, India
  • Healthcare Global Enterprises Ltd
    Bengaluru, Karnataka 560027, India
  • Amrita Institute of Medical Sciences
    Kochi, Kerala 682 041, India
  • Regional Cancer Centre - Thiruvananthapuram
    Thiruvananthapuram, Kerala 695011, India
  • Marathwada Regional Cancer Centre and Research Institute
    Aurangabad, Maharashtra 431001, India
  • Jaslok Hospital and Research Centre
    Mumbai, Maharashtra 400026, India
  • Curie Manavata Cancer Centre
    Nashik, Maharashtra 422004, India
  • Jehangir Hospital
    Pune, Maharashtra 411001, India
  • Sparsh Hospital & Critical Care
    Bhubaneswar, Odisha 751007, India
  • All India Institute of Medical Sciences
    Bhubaneswar, Odisha 751019, India
  • Jawaharlal Institute Of Postgraduate Medical Education and R
    Gorimedu, Puducherry 605006, India
  • Christian Medical Center & Hospital
    Ludhiana, Punjab 141008, India
  • Sawami Man Singh (SMS) Medical College & Attached Hospitals
    Jaipur, Rajasthan 302017, India
  • Apollo Speciality Hospitals
    Madurai, Tamil Nadu 625020, India
  • Meenakshi Mission Hospital & Research Centre
    Madurai, Tamil Nadu 625107, India
  • Post Graduate Institute of Medical Education and Research
    Chandigarh, 160012, India
  • Tata Medical Center
    Kolkata, 700156, India
  • Apex Wellness Hospital
    Nashik, 422009, India
  • Rajiv Gandhi Cancer Institute & Research Centre
    New Delhi, 110 085, India
  • Daugavpils Regional Hospital
    Daugavpils, LV-5417, Latvia
  • RAKUS Hospital Gailezers
    Riga, 1038, Latvia
  • URO Ltd.
    Riga, LV-1001, Latvia
  • P. Stradins Clinical University Hospital
    Riga, LV-1002, Latvia
  • Vidzemes Hospital
    Valmiera, LV-4201, Latvia
  • The Hospital of Lithuanian University of Health SciencesLUHS
    Kaunas, LT-50009, Lithuania
  • PI Klaipedos University Hospital
    Klaipėda, LT-92288, Lithuania
  • National Cancer Institute
    Vilnius, LT-08660, Lithuania
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, LT-08661, Lithuania
  • Tauranga Urology Research Limited
    Tauranga, Bay of Plenty 3112, New Zealand
  • Canterbury Urology Research Trust
    Christchurch, Canterbury 8013, New Zealand
  • Waikato Hospital
    Hamilton, Waikato Region 3240, New Zealand
  • Aliada
    San Isidro, Lima region 15036, Peru
  • Hospital Guillermo Almenara Irigoyen
    Santiago de Surco, Lima region 15033, Peru
  • Hospital Militar Luis Arias Schreiber
    Lima, LIMA 11, Peru
  • Clínica El Golf
    Lima, LIMA 27, Peru
  • Arkhangelsk Clinical Oncology Dispensary
    Arkhangelsk, 163045, Russia
  • Ltd "EVIMED"
    Chelyabinsk, 454048, Russia
  • Chelyabinsk Regional Oncology Dispensary
    Chelyabinsk, 454087, Russia
  • Ivanovo Regional Oncology Dispensary
    Ivanovo, 153040, Russia
  • Republican Clinical Oncology Dispensary Kazan
    Kazan', 420029, Russia

Showing the first 100 of 131 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP. Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial. Eur Urol. 2026 Aug 12:S0302-2838(26)02313-4. doi: 10.1016/j.eururo.2026.07.026. Online ahead of print. PubMed 42586872 ↗
  • Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2026 May;27(5):614-624. doi: 10.1016/S1470-2045(26)00014-8. Epub 2026 Apr 9. PubMed 41969015 ↗
  • Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP; ARANOTE Study Investigators. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 Dec 20;42(36):4271-4281. doi: 10.1200/JCO-24-01798. Epub 2024 Sep 16. PubMed 39279580 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jun 2024, 39 months.

Results were first posted in Aug 2025, 1 year 2 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 39 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 3, 2021
StartActual
Feb 23, 2021
Primary completionActual
Jun 7, 2024
CompletionActual
Jan 23, 2026
Results first posted
Aug 8, 2025
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Sep 29, 2026
Documents
Sep 29, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42586872 ↗
Sep 29, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameOverall Survival (OS)From randomization to the date when 222 rPFS events were observed, approximately 36 months → From randomization to the final analysis date, approximately 47 months
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Posted results revised
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42586872 ↗
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameOverall Survival (OS)From randomization to the date when 222 rPFS events were observed, approximately 36 months → From randomization to the final analysis date, approximately 47 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04736199
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Feb 23, 2021
Primary completion
Jun 7, 2024
Completion
Jan 23, 2026
Results posted
Aug 8, 2025
Last update
Sep 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion